<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39592027</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-0183</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>Autoimmunity reviews</Title><ISOAbbreviation>Autoimmun Rev</ISOAbbreviation></Journal><ArticleTitle>Intravenous immunglobulin as a therapy for autoimmune conditions.</ArticleTitle><Pagination><StartPage>103710</StartPage><MedlinePgn>103710</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.autrev.2024.103710</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1568-9972(24)00201-5</ELocationID><Abstract><AbstractText>Intravenous immunoglobulin (IVIg) is a medical preparation used as replacement therapy for patients with immunodeficiencies. Over time, IVIg's anti-inflammatory and immunomodulatory effects have been recognized, which have led to the approval of this therapy in the treatment of various pathologies, such as Kawasaki disease, immune thrombocytopenia, and Guillain-Barr&#xe9; syndrome. There are numerous studies in the literature regarding the off-label use of IVIg in the treatment of autoimmune diseases (e.g. myositis and vasculitis), and hematological disorders. Since the role of immunoglobulins in fields other than replacement therapy is now consolidated, in this study we carried out a review of the literature to evaluate the main uses of IVIg therapy. We have focused our attention on the treatment of autoimmune, neurological, hematological, dermatological and pediatric diseases. Furthermore, our analysis of the literature also extended to the potential use of IVIg as an adjuvant treatment of long COVID-19. From our analysis, we found consistent data about IVIg's effectiveness in treating numerous clinical conditions. Treatment with IVIg represents a second-line approach or a valid adjuvant to standard therapies capable of positively influencing the clinical course of many pathologies and reducing or avoiding side effects of standard therapies, with a good safety profile.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Danieli</LastName><ForeName>Maria Giovanna</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>SOS Immunologia delle Malattie Rare e dei Trapianti. AOU delle Marche &amp; Dipartimento di Scienze Cliniche e Molecolari, Universit&#xe0; Politecnica delle Marche, via Tronto 10/A, 60126 Torrette di Ancona, Italy; Postgraduate School of Allergy and Clinical Immunology, Universit&#xe0; Politecnica delle Marche, via Tronto 10/A, 60126 Ancona, Italy. Electronic address: m.g.danieli@univpm.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Postgraduate School of Internal Medicine, Universit&#xe0; Politecnica delle Marche, 60126 Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gammeri</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Postgraduate School of Allergy and Clinical Immunology, University of Messina, 98121 Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longhi</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Postgraduate School in Clinical Pathology and Clinical Biochemistry, Universit&#xe0; G. D'Annunzio Chieti -Pescara, 66100 Chieti, Italy. Electronic address: eleonora.longhi@studio.unibo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cozzi</LastName><ForeName>Maria Francesca</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Postgraduate School of Internal Medicine, Universit&#xe0; Politecnica delle Marche, 60126 Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmeri</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Postgraduate School of Allergy and Clinical Immunology, Universit&#xe0; Politecnica delle Marche, via Tronto 10/A, 60126 Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gangemi</LastName><ForeName>Sebastiano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125 Messina, Italy. Electronic address: sebastiano.gangemi@unime.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoenfeld</LastName><ForeName>Yehuda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel; Reichman University, Herzelia 46101, Israel. Electronic address: yehuda.shoenfeld@sheba.health.gov.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Autoimmun Rev</MedlineTA><NlmUniqueID>101128967</NlmUniqueID><ISSNLinking>1568-9972</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune disease</Keyword><Keyword MajorTopicYN="N">Immune thrombocytopenia</Keyword><Keyword MajorTopicYN="N">Immunomodulation</Keyword><Keyword MajorTopicYN="N">Intravenous immunoglobulin</Keyword><Keyword MajorTopicYN="N">Kawasaki disease</Keyword><Keyword MajorTopicYN="N">Long COVID-19</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. MG Danieli and Yehuda Shoenfeld are serving in the Editorial Board of Autoimmunity Reviews If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39592027</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2024.103710</ArticleId><ArticleId IdType="pii">S1568-9972(24)00201-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>